282 related articles for article (PubMed ID: 35631502)
1. Physiologically Based Pharmacokinetic (PBPK) Modeling of Clopidogrel and Its Four Relevant Metabolites for CYP2B6, CYP2C8, CYP2C19, and CYP3A4 Drug-Drug-Gene Interaction Predictions.
Loer HLH; Türk D; Gómez-Mantilla JD; Selzer D; Lehr T
Pharmaceutics; 2022 Apr; 14(5):. PubMed ID: 35631502
[TBL] [Abstract][Full Text] [Related]
2. Physiologically Based Pharmacokinetic Modeling of Bupropion and Its Metabolites in a CYP2B6 Drug-Drug-Gene Interaction Network.
Marok FZ; Fuhr LM; Hanke N; Selzer D; Lehr T
Pharmaceutics; 2021 Mar; 13(3):. PubMed ID: 33806634
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of the CYP3A4 and CYP2B6 Inducer Carbamazepine and Its Drug-Drug Interaction Potential: A Physiologically Based Pharmacokinetic Modeling Approach.
Fuhr LM; Marok FZ; Hanke N; Selzer D; Lehr T
Pharmaceutics; 2021 Feb; 13(2):. PubMed ID: 33671323
[TBL] [Abstract][Full Text] [Related]
4. Physiologically Based Pharmacokinetic Models for Prediction of Complex CYP2C8 and OATP1B1 (SLCO1B1) Drug-Drug-Gene Interactions: A Modeling Network of Gemfibrozil, Repaglinide, Pioglitazone, Rifampicin, Clarithromycin and Itraconazole.
Türk D; Hanke N; Wolf S; Frechen S; Eissing T; Wendl T; Schwab M; Lehr T
Clin Pharmacokinet; 2019 Dec; 58(12):1595-1607. PubMed ID: 31129789
[TBL] [Abstract][Full Text] [Related]
5. A Physiologically-Based Pharmacokinetic Model of Trimethoprim for MATE1, OCT1, OCT2, and CYP2C8 Drug-Drug-Gene Interaction Predictions.
Türk D; Hanke N; Lehr T
Pharmaceutics; 2020 Nov; 12(11):. PubMed ID: 33182761
[TBL] [Abstract][Full Text] [Related]
6. Physiologically Based Pharmacokinetic Modeling Suggests Limited Drug-Drug Interaction Between Clopidogrel and Dasabuvir.
Shebley M; Fu W; Badri P; Bow D; Fischer V
Clin Pharmacol Ther; 2017 Oct; 102(4):679-687. PubMed ID: 28411400
[TBL] [Abstract][Full Text] [Related]
7. A Physiologically Based Pharmacokinetic and Pharmacodynamic Model of the CYP3A4 Substrate Felodipine for Drug-Drug Interaction Modeling.
Fuhr LM; Marok FZ; Mees M; Mahfoud F; Selzer D; Lehr T
Pharmaceutics; 2022 Jul; 14(7):. PubMed ID: 35890369
[TBL] [Abstract][Full Text] [Related]
8. Physiologically based pharmacokinetic modeling of imatinib and N-desmethyl imatinib for drug-drug interaction predictions.
Loer HLH; Kovar C; Rüdesheim S; Marok FZ; Fuhr LM; Selzer D; Schwab M; Lehr T
CPT Pharmacometrics Syst Pharmacol; 2024 Mar; ():. PubMed ID: 38482980
[TBL] [Abstract][Full Text] [Related]
9. A Physiologically Based Pharmacokinetic Model of Voriconazole Integrating Time-Dependent Inhibition of CYP3A4, Genetic Polymorphisms of CYP2C19 and Predictions of Drug-Drug Interactions.
Li X; Frechen S; Moj D; Lehr T; Taubert M; Hsin CH; Mikus G; Neuvonen PJ; Olkkola KT; Saari TI; Fuhr U
Clin Pharmacokinet; 2020 Jun; 59(6):781-808. PubMed ID: 31853755
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of cytochrome P450 enzymes and uridine 5'-diphospho-glucuronosyltransferases by vicagrel in human liver microsomes: A prediction of potential drug-drug interactions.
Liu S; Wang Z; Chan E; Zhao Y; Kang J; Zhang X; Tian X
Chem Biol Interact; 2022 Jan; 352():109775. PubMed ID: 34910929
[TBL] [Abstract][Full Text] [Related]
11. Physiologically based pharmacokinetic modeling for sequential metabolism: effect of CYP2C19 genetic polymorphism on clopidogrel and clopidogrel active metabolite pharmacokinetics.
Djebli N; Fabre D; Boulenc X; Fabre G; Sultan E; Hurbin F
Drug Metab Dispos; 2015 Apr; 43(4):510-22. PubMed ID: 25609219
[TBL] [Abstract][Full Text] [Related]
12. Interplay of UDP-Glucuronosyltransferase and CYP2C8 for CYP2C8 Mediated Drug Oxidation and Its Impact on Drug-Drug Interaction Produced by Standardized CYP2C8 Inhibitors, Clopidogrel and Gemfibrozil.
Iga K; Kiriyama A
Clin Pharmacokinet; 2024 Jan; 63(1):43-56. PubMed ID: 37921907
[TBL] [Abstract][Full Text] [Related]
13. A Mechanistic, Enantioselective, Physiologically Based Pharmacokinetic Model of Verapamil and Norverapamil, Built and Evaluated for Drug-Drug Interaction Studies.
Hanke N; Türk D; Selzer D; Wiebe S; Fernandez É; Stopfer P; Nock V; Lehr T
Pharmaceutics; 2020 Jun; 12(6):. PubMed ID: 32560124
[TBL] [Abstract][Full Text] [Related]
14. A Physiologically Based Pharmacokinetic Model of Ketoconazole and Its Metabolites as Drug-Drug Interaction Perpetrators.
Marok FZ; Wojtyniak JG; Fuhr LM; Selzer D; Schwab M; Weiss J; Haefeli WE; Lehr T
Pharmaceutics; 2023 Feb; 15(2):. PubMed ID: 36840001
[TBL] [Abstract][Full Text] [Related]
15. Predicting the Effects of CYP2C19 and Carboxylesterases on Vicagrel, a Novel P2Y12 Antagonist, by Physiologically Based Pharmacokinetic/Pharmacodynamic Modeling Approach.
Liu S; Wang Z; Tian X; Cai W
Front Pharmacol; 2020; 11():591854. PubMed ID: 33424602
[TBL] [Abstract][Full Text] [Related]
16. Physiologically Based Pharmacokinetic Modeling of Rosuvastatin to Predict Transporter-Mediated Drug-Drug Interactions.
Hanke N; Gómez-Mantilla JD; Ishiguro N; Stopfer P; Nock V
Pharm Res; 2021 Oct; 38(10):1645-1661. PubMed ID: 34664206
[TBL] [Abstract][Full Text] [Related]
17. A physiologically based pharmacokinetic model of clopidogrel in populations of European and Japanese ancestry: An evaluation of CYP2C19 activity.
Duong JK; Nand RA; Patel A; Della Pasqua O; Gross AS
Pharmacol Res Perspect; 2022 Apr; 10(2):e00946. PubMed ID: 35307978
[TBL] [Abstract][Full Text] [Related]
18. Assessment of interaction potential of AZD2066 using in vitro metabolism tools, physiologically based pharmacokinetic modelling and in vivo cocktail data.
Nordmark A; Andersson A; Baranczewski P; Wanag E; Ståhle L
Eur J Clin Pharmacol; 2014 Feb; 70(2):167-78. PubMed ID: 24186263
[TBL] [Abstract][Full Text] [Related]
19. Physiologically Based Pharmacokinetic Modeling to Predict Drug-Drug Interactions with Efavirenz Involving Simultaneous Inducing and Inhibitory Effects on Cytochromes.
Marzolini C; Rajoli R; Battegay M; Elzi L; Back D; Siccardi M
Clin Pharmacokinet; 2017 Apr; 56(4):409-420. PubMed ID: 27599706
[TBL] [Abstract][Full Text] [Related]
20. Glucuronidation converts clopidogrel to a strong time-dependent inhibitor of CYP2C8: a phase II metabolite as a perpetrator of drug-drug interactions.
Tornio A; Filppula AM; Kailari O; Neuvonen M; Nyrönen TH; Tapaninen T; Neuvonen PJ; Niemi M; Backman JT
Clin Pharmacol Ther; 2014 Oct; 96(4):498-507. PubMed ID: 24971633
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
